Olmesartan Medoxomil Mylan (Olmesartan Medoxomil)

Olmesartan Medoxil is used to manage hypertension, a condition characterized by elevated arterial pressure.

• Hypertension: lowers blood pressure by blocking the effects of angiotensin II, helping to reduce the risk of cardiovascular events.
• Essential hypertension: provides sustained blood pressure control in patients requiring long‑term therapy.
• Primary hypertension: improves vascular tone and reduces cardiac workload.

• Olmesartan Medoxomil selectively antagonizes the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition blocks vasoconstriction and aldosterone secretion, leading to relaxation of vascular smooth muscle, reduced peripheral resistance, and ultimately a decrease in systemic blood pressure.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or lacking energy.
• Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing.
• Hyperkalemia: elevated potassium levels that can affect heart rhythm.
• Renal impairment: worsening kidney function, indicated by increased creatinine.
• Severe hypotension: markedly low blood pressure causing faintness or shock.

Olmesartan Medoxomil requires careful monitoring and patient education.

• Blood pressure monitoring: regularly check to ensure therapeutic effect and avoid excessive lowering.
• Renal function assessment: evaluate kidney function before initiating and during therapy.
• Serum potassium check: monitor potassium levels, especially when combined with potassium‑sparing agents.
• Pregnancy avoidance: do not use during pregnancy due to risk of fetal toxicity.
• Elderly caution: start at lower doses and monitor for orthostatic hypotension.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil may interact with several drug classes.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia.
• ACE inhibitors (e.g., enalapril): concurrent use heightens risk of hypotension and hyperkalemia.
• NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment.
• Lithium: can increase lithium levels, necessitating serum monitoring.
• Other antihypertensives (e.g., beta‑blockers): may require careful titration to avoid excessive hypotension.